Phase I/II trial of gefitinib and RAD001 (everolimus) in patients (pts) with advanced non-small cell lung cancer (NSCLC).

被引：0
|
作者：
Milton, DT [1 ]
Kris, MG [1 ]
Azzoli, CG [1 ]
Gomez, JE [1 ]
Heelan, R [1 ]
Krug, LM [1 ]
Pao, W [1 ]
Pizzo, B [1 ]
Rizvi, NA [1 ]
Miller, VA [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：646S / 646S
页数：1
相关论文
共 50 条
  • [1] PHASE I TRIAL OF RAD001 (EVEROLIMUS) IN COMBINATION WITH RADIOTHERAPY IN NON-SMALL CELL LUNG CANCER
    Deutsch, E.
    Lepechoux, C.
    Pignon, J. P.
    Tao, Y. T.
    Rivera, S.
    Bourgier, B. C.
    Angokai, M.
    Bahleda, R.
    Slimane, K.
    Angevin, E.
    Besse, B. B.
    Soria, J. C.
    ANNALS OF ONCOLOGY, 2013, 24 : 9 - 9
  • [2] Phase II Trial of Gefitinib and Everolimus in Advanced Non-small Cell Lung Cancer
    Price, Katharine A.
    Azzoli, Christopher G.
    Krug, Lee M.
    Pietanza, Maria C.
    Rizvi, Naiyer A.
    Pao, William
    Kris, Mark G.
    Riely, Gregory J.
    Heelan, Robert T.
    Arcila, Maria E.
    Miller, Vincent A.
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (10) : 1623 - 1629
  • [3] Characterization of Pneumonitis in Patients with Advanced Non-small Cell Lung Cancer Treated with Everolimus (RAD001)
    White, Dorothy A.
    Schwartz, Lawrence H.
    Dimitrijevic, Sasa
    Di Scala, Lilla
    Hayes, Wendy
    Gross, Stefan H.
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (11) : 1357 - 1363
  • [4] Combined inhibition of mTOR and EGFR with everolimus (RAD001) and gefitinib in patients with non-small cell lung cancer who have smoked cigarettes: A phase II trial
    Kris, M. G.
    Riely, G. J.
    Azzoli, C. G.
    Heelan, R. T.
    Krug, L. M.
    Pao, W.
    Milton, D. T.
    Moore, E.
    Rizvi, N. A.
    Miller, V. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [5] A phase I trial of gefitinib and nimotuzumab in patients with advanced non-small cell lung cancer (NSCLC)
    Kim, Se Hyun
    Shim, Hyo Sup
    Cho, Jaeho
    Jeong, Jae Heon
    Kim, Sun Mi
    Hong, Yun Kyoung
    Sung, Ji Hee
    Ha, Sang-Jun
    Kim, Hye Ryun
    Chang, Hyun
    Kim, Joo Hang
    Tania, Crombet
    Cho, Byoung Chul
    LUNG CANCER, 2013, 79 (03) : 270 - 275
  • [6] A phase I trial of gefitinib and nimotuzumab in patients with advanced non-small cell lung cancer (NSCLC).
    Kim, Han Sang
    Cho, Byoung Chul
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [7] Rationale for a phase I trial of erlotinib and the mammalian target of rapamycin inhibitor everolimus (RAD001) for patients with relapsed non-small cell lung cancer
    Johnson, Bruce E.
    Jackman, David
    Janne, Pasi A.
    CLINICAL CANCER RESEARCH, 2007, 13 (15) : 4628S - 4631S
  • [8] Phase I study of daily or weekly RAD001 (R, everolimus) in combination with pemetrexed (P) in patients with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy
    Vansteenkiste, Johan
    Solomon, Ben
    Boyer, Michael
    Wolf, Juergen
    Miller, Neil
    Di Scala, Lilla
    Petrovic, Katarina
    Dimitrijevic, Sasa
    Anrys, Beatrijs
    Laack, Eckart
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S446 - S446
  • [9] A phase II study of RAD001 (R) (everolimus) monotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) failing prior platinumbased chemotherapy (C) or prior C and EGFR inhibitors (EGFR-I)
    Papadimitrakopoulou, V.
    Soria, J. C.
    Douillard, J. Y.
    Giaccone, G.
    Wolf, J.
    Crino, L.
    Cappuzzo, F.
    Sharma, S.
    Gross, S. H.
    Shepherd, F. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [10] Phase II Study of Everolimus (RAD001) in Previously Treated Small Cell Lung Cancer
    Tarhini, Ahmad
    Kotsakis, Athanasios
    Gooding, William
    Shuai, Yongli
    Petro, Daniel
    Friedland, David
    Belani, Chandra P.
    Dacic, Sanja
    Argiris, Athanassios
    CLINICAL CANCER RESEARCH, 2010, 16 (23) : 5900 - 5907
12345